학술논문

Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT2/3 study
Document Type
Academic Journal
Source
Journal of Gastroenterology and Hepatology. Oct 01, 2013 28 Supp 2:155-156
Subject
Language
English
ISSN
0815-9319